1. (1) Each laboratory shall submit clinical material from each case identified with any organism listed in Section R386-702-4 to UPHL within three working days of identification.

2. (2)(a) Submission of clinical material is mandatory for:

   1. (i) any antibiotic-resistant organism, from any specimen, that:

      1. (A) is resistant to vancomycin in Staphylococcus aureus (VRSA);
      2. (B) is resistant to a carbapenem in:
      3. (I) Acinetobacter species;
      4. (II) any Enterobacterales organism;
      5. (III) Pseudomonas aeruginosa that is not susceptible to:
   2. (Aa) ceftolozane/tazobactam; or

   3. (Bb) cefepime or ceftazidime when ceftolozane/tazobactam resistance is unknown;

      1. (C) demonstrates carbapenemase production in:
      2. (I) Acinetobacter species;
      3. (II) any Enterobacterales organism; or
      4. (III) Pseudomonas aeruginosa;
      5. (ii) Campylobacter species;
      6. (iii) Candida auris or Candida haemulonii from any body site;
      7. (iv) Corynebacterium diphtheriae;
      8. (v) Cronobacter sakazakii, from a normally sterile site in a person less than 12 months old;
      9. (vi) Shiga toxin-producing Escherichia coli including enrichment or MacConkey broths that tested positive by any method for Shiga toxin;
      10. (vii) Haemophilus influenzae from a normally sterile site;
      11. (viii) influenza A virus, unsubtypeable;
      12. (ix) influenza virus in a hospitalized case;
      13. (x) Legionella species;
      14. (xi) Listeria monocytogenes;
      15. (xii) measles (rubeola);
      16. (xiii) Mycobacterium tuberculosis complex;
      17. (xiv) Neisseria meningitidis, from a normally sterile site;
      18. (xv) Salmonella species;
      19. (xvi) any SARS-CoV-2 NAAT-positive sample;
      20. (xvii) Shigella species;
      21. (xviii) Vibrio species;
      22. (xix) West Nile virus;
      23. (xx) Yersinia species;
      24. (xxi) Zika disease;
      25. (xxii) any organism implicated in an outbreak when instructed by authorized local or state health department personnel; or

      26. (xxiii) any potential bioterrorism agent, including:

          1. (A) Bacillus anthracis;
          2. (B) Brucella species;
          3. (C) Clostridium botulinum;
          4. (D) Francisella tularensis; and
          5. (E) Yersinia pestis.
   4. (b) The department may suspend or modify mandatory submission requirements.

3. (3) If a laboratory identifies a case with an organism designated by UPHL as a potential bioterrorism agent, the laboratory shall immediately notify UPHL by phone before submitting clinical material from the case.

   1. (a) During business hours, the phone number for UPHL is 801-965-2400.
   2. (b) After hours, the phone number for UPHL is 801-560-6586.
4. (4) Submission of clinical material does not replace the requirement for laboratories to report the event to the department as specified in Sections R386-702-7 and R386-702-8.
5. (5) For additional information on the process described in this section, contact UPHL at 801-965-2400.

KEY: communicable diseases, quarantines, rabies, rules and procedures

Date of Last Change: June 1, 2026

Notice of Continuation: March 2, 2026

Authorizing, and Implemented or Interpreted Law: 26B-1-202; 26B-7-202; 26B-7-207; 26B-7-303 through 26B-7-315; 26B-7-316 through 26B-7-324